drugset / Trial / NCT06311929

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

NCT06311929

Phase 4 Recruiting 300 enrolled Chen Xiaoping
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.

Timeline

Start
2024-04-01
Primary completion
2027-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule Oral